Shares of Novo Integrated Sciences Inc. (NASD: NVOS) are up today in pre-market trading at $0.2885. After losing -4.07% to end the regular trading session at $0.28, NVOS has risen 7.74% to $0.305 in the after-hours market on Wednesday.
What current events took place at NVOS?
Last week, Novo Integrated Sciences (NVOS) disclosed the pricing for its public offering of a total of 4,000,000 shares at a price of $0.50 per unit. There is one share of common stock for each unit (or one pre-funded warrant in lieu thereof). Furthermore, it consists of two warrants: one warrant to buy one share of common stock, immediately exercisable at a price of $0.50 per share and expiring five years after the date of issuance; and one warrant, which will immediately separate upon issuance, to buy one share of common stock, immediately exercisable at a price of $0.50 per share and expire three years after the date of issuance.
Depending on the fulfillment of customary closing conditions, the offering’s closing was projected to take place on or around October 18, 2022. Before subtracting the placement agent’s commission and other selling costs, it was anticipated that the total proceeds from the offering would be close to $2.0 million. The Company had plans to use the net proceeds of the offering for general business objectives, including potential future strategic acquisitions, debt reduction, and other company-wide needs. The only placement agent for the offering is Maxim Group LLC which was represented by Harter Secrest & Emery LLP, while Novo Integrated Sciences was represented by Anthony L. G., PLLC.
Recently, NVOS inked a contract:
Through its fully owned subsidiary Clinical Consultants International (‘CCI’), Novo also this month announced the signing of a Consulting Services Agreement (the “Agreement”). With Softhread, Inc., an information technology firm that provides a proprietary, patent-pending blockchain and AI-enabled platform that maintains confidentiality and enhances network security while boosting operational efficiency, the Agreement includes the possibility of revenue sharing. The Agreement refers to Softhread’s product and service offerings relevant to the quickly changing worldwide medical communities as they enter the new era of connected, smart healthcare delivery, or “Health Care 4.0.”
What made it easier for NVOS to get the deal?
The CCI team continues to give Novo Integrated Sciences (NVOS) access to crucial medical community contacts both domestically and abroad. Cybersecurity, artificial intelligence, and blockchain architecture are all crucial elements of substantially enhancing the privacy, security, and speed of data management in networks as the healthcare business accepts the fundamental transformation of smart and connected healthcare delivery. Through this Agreement, Softhread’s award-winning, recognized technologists and business executives will collaborate with CCI’s team of highly regarded, established medical professionals, led by Dr. Chalil, to introduce the Softhread platform to the medical community globally.
